Add Yahoo as a preferred source to see more of our stories on Google. In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, ...

Compared to daily oral pre-exposure prophylaxis (PrEP), lenacapavir reduces the number of new HIV infections by many more; causes slightly fewer serious unwanted effects; and results in little to no ...

Lenacapavir could put the end of the HIV epidemic in reach — if the people who need it can access it. Here’s one way to make ...

Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and ...

Michael Montess receives funding from the Canadian Institutes of Health Research, Mitacs, the Social Sciences and Humanities Research Council, and the Michael Smith Foundation for Health Research. He ...

The US Food and Drug Administration has approved the first injectable medication for pre-exposure prophylaxis (PrEP) to lower the risk of getting HIV through sex, it announced Monday. Apretude is ...

The US Food and Drug Administration has approved a form of PrEP that requires injections every two months, rather than a daily pill. PrEP, or pre-exposure prophylaxis, uses antiretroviral medications ...

Rwanda's nationwide rollout of long-acting injectable PrEP, Cabotegravir, marks a significant step forward in the fight against HIV/AIDS. However, this development highlights a deeper truth: ending ...

Add Yahoo as a preferred source to see more of our stories on Google. A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully passed an ...

A nurse at Tudor Sub-County Hospital in Mombasa administers Lenacapavir injection during the rollout of the vaccine on March 13, 2026. [Robert Menza, Standard] Mombasa County has officially rolled out ...

A recent study of injectable pre-exposure prophylaxis found that twice-yearly injections of lenacapavir — marketed as Yeztugo by Gilead Sciences — do not have clinically significant interactions with ...